Drugs to 'transform' fragile X syndrome market named by GlobalData

22 February 2022

By 2030, GlobalData has predicted that promising pipeline drugs Zygel (cannabidiol gel), zatolmilast, trofinetide, and acamprosate calcium SR will offer new treatment options for people with Fragile X Syndrome (FXS), a rare genetic disorder that is the leading cause of inherited intellectual disability.

The data and analytics company expects these products to help propel the growth of the FXS market, adding around $23.3 million to its value by 2030.

"A new dynamic market with a variety of options for patients"Christie Wong, neurology analyst at GlobalData, said: “There are a number of exciting pipeline drugs for the treatment of FXS that will transform the market over the next decade. For example, GlobalData expects Zynerba Pharmaceuticals’ (Nasdaq: ZYNE) Zygel will be the first to market, with a primary completion date for its Phase III trial expected in September 2023. Zygel could offer an important therapeutic option for patients who are the most severely impacted with FXS and could bring in sales of $18.1 million by 2030.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK